Porphyromonas gingivalis proteins

Porphyromonas gingivalis proteins represent a broad class of virulence factors produced by the anaerobic bacterium Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis (Lamont et al., 2018, Nature Reviews Microbiology). The most clinically significant proteins are the gingipains, a group of cysteine proteases (Kgp, RgpA, and RgpB) that degrade host tissues and subvert the immune system by cleaving cytokines, complement factors, and cell surface receptors. Research has increasingly linked these proteins to systemic diseases, most notably Alzheimer's disease, where P. gingivalis DNA and gingipains have been identified in the brains of affected individuals and associated with neuroinflammation and tau pathology (Dominy et al., 2019, Science Advances). Therapeutic efforts have focused on developing small-molecule gingipain inhibitors, such as Atuzaginstat, to reduce the bacterial load and halt the inflammatory cascade. However, clinical development has faced significant challenges, including safety concerns regarding liver enzyme elevations and inconsistent efficacy results in large-scale clinical trials (Cortexyme, 2022, GAIN Trial results).

Other names

P. gingivalis virulence factorsP. gingivalis proteasesGingipainsPg proteins

Small-molecule inhibitors target specific Porphyromonas gingivalis proteases (gingipains) by irreversibly binding to their active sites, thereby preventing the degradation of host immune proteins and neural tissues. (Dominy et al., 2019, Science Advances)